Brussels, 09/01/2013 (Agence Europe) - The European Commission expects the Court of Justice of the EU to return its ruling this year on the authorisation for sale on the European market of Orphacol, a drug produced by the French laboratory CTRS and designed to treat two orphan liver diseases, which are extremely rare and serious (affecting no more than around 100 people in the European Union). This was announced on Wednesday 9 January by Frédéric Vincent, the spokesperson to Tonio Borg,...